The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"I think we need to look at market segmentation here now also. In essence ODX now have a distribution partner for a completely different market segment (ELISA antibody, likely quantitative test compared to LFT qualitative) and can expect the partner to focus on marketing activities for this whilst they focus on the LFTs."
Yep - absolutely. And don't forget that just a few weeks/months ago, many people were writing off the ELISA aspect of the portfolio.
spinning and twisting so much I'll not be surprised if you disappear up your own ar*e
I think we need to look at market segmentation here now also. In essence ODX now have a distribution partner for a completely different market segment (ELISA antibody, likely quantitative test compared to LFT qualitative) and can expect the partner to focus on marketing activities for this whilst they focus on the LFTs.
No one really knows the true value of this new contract. The reality is ODX have an income source today that was not there yesterday. It may be £10 in may be £10m. It has to be better to have an additional income route that is it is not too have one. Also perhaps better to have more smaller income routes than just one big one. Even if we do not get any business from them we are still no worse off than we were yesterday. In my opinion it has to be positive. How positive time will tell
Twatcher - the fact is to get one contract with one large number on is very rare. It's not a gov contract its a normal contract in the normal course of a new business stream. They cannot possibly put a value on it as it is dependant on demand because of the nature of the service and customer. This is very different to a UK gov contract where they know upfront they will be ordering a certain number of millions. Nobody is claiming this is going to be worth hundreds of millions in the next 6 months, but genuine investors will be pleased at another revenue stream that they are probably not using in their forecast valuations. Whether it brings in £100k or £10m this year nobody knows, not us, not Omega, not Screen4, but we would all rather know about it than not. We know it is a competitive test with huge potential with the home test sample approval. We know antibody testing is still in its infancy and we know it still has a bigger role to play, and that this lab service can offer solutions to some of the concerns of LFT. So there is plenty to be positive about.
The launch of the very lab service was RNS reach - nobody had a problem with it then. Last 2 ABC updates, Reach.
"It's not regulatory like delivering financials or PDMR dealings."
Significant contracts are ALWAYS RNS-ed, because it is a market requirement, exactly because they affect future financials in
a significant way that was not previously advised to the market.
Some people will argue black is white to serve their purpose.
from the bottom of the RNS-non
"Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature"
TCO, they did have traction for Screen4. They are selling their tests for £54.00. I must admit ODX will make more of this news when it puts the scale and pricing policy of the contract into the public domain.
Seriously am i reading people discrediting the rns because its an RNS reach rather than a regulatory RNS? Go and look at several other RNS. RNS reach is exactly the right service for this information. It's not regulatory like delivering financials or PDMR dealings.
People moan we dont get contract update and they moan when we do. Any mug can see they can't put a value on it and announce numbers because they cannot predict the future.
https://www.lseg.com/areas-expertise/market-information/regulatory-news-service/reach
S4 outlets
* Barnsley – 17 Middlewoods Way, Barnlsey, S71 3HR
* Birmingham – 26 High St, Sutton Coldfield B72 1UP – CURRENTLY CLOSED
* Cambridge – Unit 13B, Dencora Business Centre, Nuffield Road, Cambridge, CB4 1TG
* Cirencester – Estate Farm, West Lane, Kemble, Cirencester, Gloucestershire, GL7 6AB
* Harlow – Lobby Office, Westgate House, West Square, Harlow, Essex, CM20 1YS – CURRENTLY CLOSED
* London – Lower Ground Floor Office, 109-111 Fulham Palace Road, Hammersmith, London, W6 8JA
* Manchester – Office 21, 2nd Floor “The Building” HQ, Clippers Quay, Salford Quays, Manchester, M50 3XP
Partnership with Virgin - https://screen4.org/virgin-atlantic-passengers-pre-travel-pcr-testing/
Virgins Partners site - https://flywith.virginatlantic.com/gb/en/news/coronavirus/covid-19-testing.html
S4 charges for a PCR - https://screen4.org/product/covid-19-pre-travel-clinician-test/
Stats for Virgin flights, can't find any info on 2021 flights, but you would expect in the coming weeks and months for flights to get back to some normality.
https://www.statista.com/statistics/309373/virgin-atlantics-uk-passenger-numbers/
The question is - Take your PCR, and by the way we also offer a test for when you are away on your journey, how many would you like?
It's at the bottom of the narrative on the RNS
TWatcher, can you let me know how to find out when an RNS is categorised as ‘non’.
TIA
Just be mindful that the ELISA tests before didn't have much traction last year. However lets hope that the tide has turned in 2021.
I think they only RNS it in order to tweet the sh@t out of it lol
I'm also curious of the potential longevity/demand of this service If MHRA approval is given for home use of ABC. Of course that would also mean massive potential demand for ABC so good position to be in.
https://screen4.org/product/finger-prick-antibody-test/
£52.00 for joe blogs and his concubine.
B2B - I doubt very much that is the price. They have some nice exposure - https://screen4.org/sectors/
If you are the director of S4, and you are eating your porridge, mulling over the B2C - Do I take out a few adds in the national newspapers over the weekend, do I get into bed with one and they get a % slice of sales (free pass on an ad campaign) - With £52 as a starting point, free P&P can be offered, maybe I will do a buy 1, get the second half price. Maybe with my margins sky high and I got a pair of boxers for my birthday with a steel ball image on front, I go straight into a TV add campaign, maybe C5, don't need it high key, the PR after effect will drive the press to pick it up.
Options, terrible thing in business.
Basically!
"It isn’t a fixed volume contract so Omega will fulfil orders from Screen4 according to demand. "
so its the testing service equivalent of a zero hrs contract.
Not a bit of wonder it came out as an RNS-non.
Morning all! Please see response from Walbrook regarding Screen 4 contract.
Morning Scott,
It isn’t a fixed volume contract so Omega will fulfil orders from Screen4 according to demand. The information on the sales value per test to Screen4 has not been disclosed.
You can see the selling price from Screen4 here: Home Use – Finger Prick Antibody Test – Screen4
Kind regards,
Alice
Alice Woodings
Associate
D: +44 (0)20 7933 8785
M: +44 (0)7407 804 654
www.walbrookpr.com
twitter.com/WalbrookPR